13F Holdings
中文EN

ABVX Abivax S.A. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1956827 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-90.7%
TTM EPS YoY-72.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-135.6%
ROA-85.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.1%
Debt / equity0.00x
Current ratio8.75x
Interest coverage-2.15x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-44.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue—————
R&D expense177.76M146.53M103.18M48.30M47.78M
SG&A expense67.67M32.95M22.39M7.49M5.58M
Operating income-246.06M-172.98M-127.38M-64.84M-41.40M
Interest expense111.74M16.99M27.88M7.02M3.56M
Pretax income-330.25M-176.24M-147.74M-60.74M-42.45M
Income tax5.85M0000
Net income-336.10M-176.24M-147.74M-60.74M-42.45M
EBITDA-244.98M-171.88M-126.67M-64.35M-41.10M
EPS (basic)-4.83-2.80-3.43-3.18-2.75
EPS (diluted)-4.83-2.80-3.43-3.18-2.75
Weighted avg. shares (diluted)69.53M63.05M43.07M19.09M15.46M
Balance sheet
Cash & equivalents516.68M144.22M251.94M26.95M60.70M
Short-term investments0136,000136,00000
Current assets551.24M170.67M285.97M36.18M75.48M
PP&E, netmay include right-of-use assets (IFRS)2.09M2.67M878,0001.59M305,000
Goodwill18.42M18.42M18.42M18.42M32.01M
Intangibles6.61M6.61M6.60M6.61M93,000
Total assets584.34M205.23M327.06M75.54M109.23M
Current liabilities63.02M94.00M90.69M51.46M32.27M
Total liabilities129.14M164.64M131.05M68.36M83.30M
Shareholders' equity455.20M40.58M196.01M7.19M25.93M
Shares outstanding—63.35M62.92M22.30M16.76M
Cash flow statement
Operating cash flow-161.13M-154.07M-97.13M-53.94M-45.05M
Capital expenditure142,000640,000265,000288,00047,000
Free cash flow-161.27M-154.71M-97.39M-54.22M-45.09M
Investing cash flow-8.19M15.76M-8.10M-12.03M-6.23M
Financing cash flow547.31M28.21M335.29M32.21M82.68M
Depreciation & amortization1.07M1.10M707,000485,000302,000
Stock-based compensation35.40M20.22M8.18M-1.16M828,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.